| dc.contributor.author | Moyo, Enos | |
| dc.contributor.author | Barham, Leela | |
| dc.contributor.author | Mhango, Malizgani | |
| dc.date.accessioned | 2022-10-03T12:14:06Z | |
| dc.date.available | 2022-10-03T12:14:06Z | |
| dc.date.issued | 2022 | |
| dc.identifier.citation | Moyo, E. et al. (2022). Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023). Journal of Infection and Public Health, 15(10), 1147-1155. https://doi.org/10.1016/j.jiph.2022.09.003 | en_US |
| dc.identifier.issn | 1876-0341 | |
| dc.identifier.uri | https://doi.org/10.1016/j.jiph.2022.09.003 | |
| dc.identifier.uri | http://hdl.handle.net/10566/8000 | |
| dc.description.abstract | Namibia started implementing pre-exposure prophylaxis (PrEP) of Human
Immunodeficiency Virus (HIV) in 2016, no study to determine its budget impact has been conducted. This
study, therefore, aimed to estimate the budget impact of adopting tenofovir/emtricitabine for PrEP of HIV
for all eligible people in the public health sector in Namibia from 2021 to 2023.
Methods: A country-specific model was developed for this budget impact analysis (BIA). PrEP has targeted
all eligible people in Namibia who receive health services from the public sector. It was assumed that the
adherence rate was 75% and PrEP effectiveness 60% in this study. Costs used in this study were taken from a
study that included Namibian costs. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | HIV | en_US |
| dc.subject | Public health | en_US |
| dc.subject | PrEP | en_US |
| dc.subject | Namibia | en_US |
| dc.subject | Public sector | en_US |
| dc.title | Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023) | en_US |
| dc.type | Article | en_US |
